Add like
Add dislike
Add to saved papers

Bariatric metabolic surgery more effective than medical therapy and lifestyle modifications for non-alcoholic steatohepatitis

2 Minute Medicine 2023 June 10

1. Patients in the sleeve gastrectomy and Roux-en-Y bypass groups reported significantly greater resolution of NASH compared to those in the lifestyle plus medical intervention group.

2. 70% of patients in the surgical group achieved NASH resolution at the 1-year follow-up.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Non-alcoholic steatohepatitis (NASH) is a form of chronic liver disease with a high burden of morbidity and eventual mortality. Although weight loss is generally recommended in these patients, the role of specific surgical or pharmacologic interventions remains unclear. This randomized controlled trial aimed to compare the safety and efficacy of bariatric metabolic surgery versus medical therapy and lifestyle modifications on patients with biopsy-proven non-alcoholic steatohepatitis (NASH). The primary outcome was the resolution of NASH at 1-year follow-up while the key secondary outcome included improvement in liver fibrosis. According to study results, bariatric surgery, both sleeve gastrectomy and Roux-en-Y bypass groups, resulted in significantly improved NASH resolution compared to medical therapy and lifestyle interventions alone. This study was strengthened by a randomized design with comparative baseline demographics between surgical and non-surgical patients, adding to its validity.

Click to read the study in The Lancet

Relevant Reading: A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

In-depth [randomized-controlled trial]: Between Apr 15, 2019, and Jun 21, 2021, 431 patients were screened for eligibility across 3 hospitals in Rome, Italy. Included were patients ≥ 25 years with a BMI of 30-55 kg/m2 and histologically confirmed NASH. Altogether, 288 patients (96 in the lifestyle modification plus medical care group, 96 in the Roux-en-Y bypass group, and 96 in the sleeve gastrectomy group) were included in the final analysis. The primary outcome of NASH resolution was greatest in the sleeve gastrectomy group (3.67 times greater, 95% confidence interval [CI] 2.23-6.02, p<0.0001), followed by Roux-en-Y gastric bypass (3.60 times greater, 95% CI 2.19-5.92, p<0.0001), compared with the lifestyle modification group. Moreover, significantly more patients in the Roux-en-Y gastric bypass group and sleeve gastrectomy group (70% for both groups) achieved resolution versus the lifestyle modification group (19%). There were no deaths reported. Findings from this study suggest that bariatric surgery is more effective than lifestyle interventions for the treatment of NASH.

Originally Published By 2 Minute Medicine®. Reused on Read by QxMD with permission.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Add to Saved Papers

Get 1-tap access

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app